You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雙鷺藥業(002038.SZ):替莫唑胺膠囊擬中標第四批全國藥品集中採購
格隆匯 02-03 20:47

格隆匯 2 月 3日丨雙鷺藥業(002038.SZ)公佈,公司202123參加了聯合採購辦公室(“聯採辦”)組織的第四批全國藥品集中採購的投標工公司產品替莫唑胺膠囊(20mg,100mg)擬中標此次集中採購。

公司擬中標的替莫唑胺2019年度銷售收入11348.57萬元(12.92萬盒),約佔2019年公司銷售收入的5.65%20201-3季度銷售收入9544.49萬元(11.34萬盒),約佔公司20201-3季度銷售收入的11.63%

根據758家樣本醫院CPT數據,替莫唑胺2019年銷售額為17.75億元,其中江蘇天士力帝益藥業有限公司佔比57.21%,沙默東有限公司佔比40.79%公司佔比6.06%

次集中採購是國家組織的第四批藥品集中帶量採購,採購週期中,醫療機構將優先使用此次藥品集中採購中選藥品,並確保完成約定採購量。此次公司擬中選價格與本次集採最高限價下降62.0%。由於公司目前該產品的市場佔比較小,若公司此次中標後續簽訂採購合同並實施後,將有利地促進替莫唑胺的銷售,有有力地提高公司該產品的市場佔有率,促進替莫唑胺在國內市場的開拓,提升公司的品牌影響力,對公司的未來經營業績產生較大的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account